Deregulated Estrogen Receptor α and p53 Heterozygosity Collaborate in the Development of Mammary Hyperplasia

被引:20
作者
Diaz-Cruz, Edgar S. [1 ]
Furth, Priscilla A. [1 ,2 ]
机构
[1] Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20057 USA
[2] Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Med, Washington, DC 20057 USA
关键词
CARCINOMA IN-SITU; TUMOR-SUPPRESSOR GENE; HUMAN BREAST-CANCER; DUCTAL CARCINOMA; CELL-PROLIFERATION; MOUSE MODEL; EXPRESSION; MICE; APOPTOSIS; RISK;
D O I
10.1158/0008-5472.CAN-09-3450
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Both increased estrogen receptor alpha (ER alpha) expression and germline disruption of one p53 allele increase breast cancer risk in women. Genetically engineered mouse models of deregulated ER alpha expression and p53 haploinsufficiency were used to investigate similarities and differences of each genetic lesion alone and in combination on mammary preneoplasia development. Each genetic lesion independently and in combination led to development of age-dependent preneoplasia, but the highest prevalence was found in compound mice with increased ER alpha expression coupled with p53 heterozygosity. All genetic lesions were associated with extracellular signal-regulated kinase 1/2 activation; however, only p53 heterozygous and compound mice showed increased levels of phosphorylated AKT and decreased p27 expression. The highest levels of cell proliferation were found in compound mice, but increased levels were also found with either increased ER alpha expression or p53 heterozygosity. Mice with increased ER alpha expression showed predicted higher levels of nuclear-localized ER alpha, but this was attenuated in compound mice in association with a relative increase in Src phosphorylation. Parity protection was limited to p53 heterozygous mice and not found in mice with increased ER alpha alone. In summary, increased and deregulated ER alpha collaborates with p53 heterozygosity in increasing the risk of mammary preneoplasia development. Cancer Res; 70(10); 3965-74. (C) 2010 AACR.
引用
收藏
页码:3965 / 3974
页数:10
相关论文
共 52 条
[11]   THE P53 TUMOR-SUPPRESSOR GENE IN BREAST-CANCER [J].
ELLEDGE, RM ;
ALLRED, DC .
BREAST CANCER RESEARCH AND TREATMENT, 1994, 32 (01) :39-47
[12]   Novel actions of estrogen to promote proliferation: Integration of cytoplasmic and nuclear pathways [J].
Fox, Emily M. ;
Andrade, Josefa ;
Shupnik, Margaret A. .
STEROIDS, 2009, 74 (07) :622-627
[13]  
Frech MS, 2005, CANCER RES, V65, P681
[14]   The p53 pathway in breast cancer [J].
Gasco, M ;
Shami, S ;
Crook, T .
BREAST CANCER RESEARCH, 2002, 4 (02) :70-76
[15]   Breast cancer incidence, 1980-2006: Combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status [J].
Glass, Andrew G. ;
Lacey, James V., Jr. ;
Carreon, Daniel ;
Hoover, Robert N. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (15) :1152-1161
[16]  
GREENBLATT MS, 1994, CANCER RES, V54, P4855
[17]   A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology [J].
Gunther, EJ ;
Belka, GK ;
Wertheim, GBW ;
Wang, J ;
Hartman, JL ;
Boxer, RB ;
Chodosh, LA .
FASEB JOURNAL, 2002, 16 (03) :283-292
[18]   MEDICAL PROGRESS .1. BREAST-CANCER [J].
HARRIS, JR ;
LIPPMAN, ME ;
VERONESI, U ;
WILLETT, W .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (05) :319-328
[19]   Predicting relapse in ductal carcinoma in situ patients: an analysis of biologic markers with long-term follow-up [J].
Hieken, Tina J. ;
Cheregi, John ;
Farolan, Miguel ;
Kim, Joan ;
Velasco, Jose M. .
AMERICAN JOURNAL OF SURGERY, 2007, 194 (04) :504-506
[20]   Conditional over-expression of estrogen receptor alpha in a transgenic mouse model [J].
Hruska, KS ;
Tilli, MT ;
Ren, S ;
Cotarla, I ;
Kwong, T ;
Li, ML ;
Fondell, JD ;
Hewitt, JA ;
Koos, RD ;
Furth, PA ;
Flaws, JA .
TRANSGENIC RESEARCH, 2002, 11 (04) :361-372